STOCKHOLM, March 19, 2024 /PRNewswire/ -- BioArctic AB (publ) (STO: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, was awarded the European Grand Prix for his research on ...
STOCKHOLM, June 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025 Hartwig ...
This year’s “Hartwig Piepenbrock-DZNE Prize”, endowed with 60,000 euros, goes to Swedish medical scientist Lars Lannfelt for his pioneering contributions to the understanding of Alzheimer’s disease ...
STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement Award ...
Lars Lannfelt succeeded in understanding what causes Alzheimer's disease as early as the 1990's. At the time he also got the idea to develop an antibody that could slow down the progression of the ...
STOCKHOLM, March 12, 2025 /PRNewswire/ -- Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) two founders, Lars Lannfelt and Pär Gellerfors, as well as the ...
Swedish scientist and physician Lars Lannfelt has received the “Hartwig Piepenbrock-DZNE Prize”, worth 60,000 euros. With this award, DZNE and the Piepenbrock Group recognize Lannfelt’s pioneering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results